Madrigal Pharmaceuticals stock price target raised by Canaccord on MASH drug outlook

Canaccord Genuity raised its price target on Madrigal Pharmaceuticals (MDGL) to $526, maintaining a Buy rating, citing strong confidence in its MASH drug Rezdiffra's competitive advantages, including efficacy, safety, and oral administration. This upgrade follows recent positive catalysts such as robust Q2 2025 sales of $212.8 million and European Union approval, with analysts projecting Rezdiffra to reach peak U.S. sales of $5.1 billion by 2032. While most firms are bullish on MDGL's market position and growth prospects, Cantor Fitzgerald maintains a Neutral rating, highlighting concerns over the drug's weight-based dosing patent.

Analysis

Madrigal Pharmaceuticals (MDGL) is experiencing significant positive momentum, driven by a series of analyst upgrades and strong commercial execution for its MASH drug, Rezdiffra. Canaccord Genuity raised its price target to $526, citing the drug's competitive advantages in efficacy, safety, and oral administration. This bullish sentiment is echoed by TD Cowen, Citizens JMP, and H.C. Wainwright, who have also increased price targets following key catalysts. The drug's recent approval in the European Union, making it the first-in-class treatment for noncirrhotic MASH across 27 EU countries, opens a significant new market, with a German launch planned for the next quarter. In the U.S., Rezdiffra's commercial performance is robust, achieving $212.8 million in sales for Q2 2025 and capturing approximately 7% of the target patient market. Canaccord projects peak U.S. sales of $5.1 billion by 2032, even after conservatively factoring in a 25% price reduction post-2033 due to the Inflation Reduction Act. The company's financial position appears solid, with a current ratio of 5.11 indicating strong liquidity to support its commercialization efforts. However, a note of caution is introduced by Cantor Fitzgerald's "Neutral" rating, which focuses on a debate over a new weight-based dosing patent, signaling a potential long-term intellectual property risk despite the otherwise positive outlook.

Key Decisions for Investors

• Given the strong initial U.S. sales of Rezdiffra, its landmark first-in-class approval in the EU, and multiple analyst upgrades, investors could interpret these events as strong validation of the drug's significant commercial potential.
• It is critical to monitor developments surrounding the company's weight-based dosing patent expiring in 2045, as this has been identified by at least one research firm as a key debate point that could impact long-term value.
• With the stock trading near its 52-week high following an 87% gain over the past year, investors should weigh the positive growth catalysts against valuation and the mentioned "crowded competitive landscape" for MASH treatments.